Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/jcm11061484
Keywords
age-related macular degeneration; genomics; non-coding RNAs; biomarkers; therapeutics
Categories
Funding
- Macular Degeneration Foundation, Inc. (Henderson, NV, USA)
- Carl Marshall Reeves & Mildred Almen Reeves Foundation, Inc. (Fenton, MO, USA)
- NIH/NEI [1K08EY031800-01]
Ask authors/readers for more resources
Age-related macular degeneration (AMD) is a leading cause of blindness in the aging population. Specific prognostic tools and effective therapies for intermediate and advanced stages of AMD are needed. Recent clinical trials have shown promising results with anti-C5 and anti-C3 agents in slowing the growth of advanced AMD, but they may increase the incidence of wet AMD. Further research on the role of non-coding RNAs (ncRNAs) in AMD is crucial for developing biomarkers and therapeutic targets.
Age-related macular degeneration (AMD) is a progressive neurodegenerative disease that is the world's leading cause of blindness in the aging population. Although the clinical stages and forms of AMD have been elucidated, more specific prognostic tools are required to determine when patients with early and intermediate AMD will progress into the advanced stages of AMD. Another challenge in the field has been the appropriate development of therapies for intermediate AMD and advanced atrophic AMD. After numerous negative clinical trials, an anti-C5 agent and anti-C3 agent have recently shown promising results in phase 3 clinical trials, in terms of slowing the growth of geographic atrophy, an advanced form of AMD. Interestingly, both drugs appear to be associated with an increased incidence of wet AMD, another advanced form of the disease, and will require frequent intravitreal injections. Certainly, there remains a need for other therapeutic agents with the potential to prevent progression to advanced stages of the disease. Investigation of the role and clinical utility of non-coding RNAs (ncRNAs) is a major advancement in biology that has only been minimally applied to AMD. In the following review, we discuss the clinical relevance of ncRNAs in AMD as both biomarkers and therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available